TNXP Tonix Pharmaceuticals Holding Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1430306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY318.0%
TTM net income YoY-82.4%
TTM EPS YoY-104.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin89.3%
Operating margin-436.3%
Net margin-420.4%
FCF margin-395.0%
EBITDA margin-431.0%
Returns
ROE-84.1%
ROA-73.1%
ROIC (approx.)-387.9%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.7%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue11.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17.23M | $13.54M | $6.88M | $5.39M | $3.29M | $2.00M | $2.43M | $2.58M |
| Cost of revenue | $1.25M | $703,000 | $1.58M | $1.06M | $1.37M | $3.27M | $943,000 | $1.18M |
| Gross profit | $15.98M | $12.84M | $5.30M | $4.33M | $1.92M | -$1.27M | $1.49M | $1.40M |
| R&D expense | $25.82M | $19.42M | $18.21M | $16.94M | $9.29M | $10.82M | $7.44M | $8.30M |
| SG&A expense | $45.59M | $35.96M | $28.62M | $35.68M | $25.70M | $16.20M | $10.10M | $15.58M |
| Operating income | -$55.43M | -$42.53M | -$41.54M | -$48.29M | -$33.07M | -$28.30M | -$16.05M | -$22.48M |
| Interest expense | — | — | — | $0 | — | — | — | $280,000 |
| Net income | -$53.33M | -$40.55M | -$40.19M | -$46.91M | -$32.01M | -$28.27M | -$16.83M | -$22.11M |
| EBITDA | -$54.83M | -$41.94M | -$40.98M | -$47.80M | -$32.67M | -$27.80M | -$15.56M | -$21.98M |
| EPS (basic) | -2.89 | -2.44 | -2.93 | — | -3.59 | -3.86 | -2.84 | — |
| EPS (diluted) | -2.89 | -2.44 | -2.93 | — | -3.59 | -3.86 | -2.84 | — |
| Weighted avg. shares (diluted) | 18.44M | 16.64M | 13.71M | — | 8.92M | 7.33M | 5.93M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $162.79M | $176.23M | $185.47M | $207.64M | $191.35M | $126.24M | $131.72M | $99.68M |
| Receivables | $14.60M | $11.80M | $8.82M | $6.27M | $3.48M | $2.32M | $3.31M | $3.68M |
| Inventory | — | — | — | — | — | — | — | $8.41M |
| Current assets | $192.13M | $203.43M | $207.17M | $228.88M | $208.07M | $143.53M | $149.57M | $119.00M |
| PP&E, net | $44.89M | $44.76M | $44.89M | $44.46M | $42.57M | $42.34M | $41.77M | $42.25M |
| Intangibles | $120,000 | $120,000 | $120,000 | $120,000 | $120,000 | $120,000 | $120,000 | $120,000 |
| Total assets | $242.43M | $254.09M | $257.91M | $277.17M | $252.44M | $187.36M | $192.87M | $162.89M |
| Current liabilities | $42.03M | $30.79M | $29.65M | $30.84M | $21.03M | $19.06M | $12.15M | $18.31M |
| Short-term debt | — | — | — | — | — | — | — | $2.82M |
| Long-term debt | — | — | — | — | — | — | — | $4.67M |
| Total debt | — | — | — | — | — | — | — | $7.49M |
| Total liabilities | $42.94M | $31.81M | $30.77M | $32.02M | $21.30M | $19.36M | $12.47M | $23.33M |
| Shareholders' equity | $199.49M | $222.28M | $227.14M | $245.15M | $231.14M | $168.00M | $180.40M | $139.56M |
| Net debt | — | — | — | — | — | — | — | -$92.19M |
| Shares outstanding | 19.15M | 16.79M | 14.21M | 12.79M | 10.17M | 7.55M | 6.88M | 4.39M |
| Cash flow statement | ||||||||
| Operating cash flow | -$41.07M | -$42.24M | -$42.32M | -$39.65M | -$28.78M | -$14.83M | -$16.58M | -$14.63M |
| Capital expenditure | $603,000 | $587,000 | $1.69M | $1.87M | $962,000 | $527,000 | $6,000 | $3,000 |
| Free cash flow | -$41.68M | -$42.83M | -$44.01M | -$41.52M | -$29.74M | -$15.36M | -$16.59M | -$14.63M |
| Investing cash flow | -$603,000 | -$587,000 | -$1.69M | -$1.02M | -$962,000 | -$2.54M | -$6,000 | -$3,000 |
| Financing cash flow | $28.28M | $33.51M | $20.20M | $59.14M | $94.86M | $10.99M | $49.53M | $85.15M |
| Depreciation & amortization | $600,000 | $600,000 | $555,000 | $488,000 | $400,000 | $500,000 | $493,000 | $496,000 |
| Stock-based compensation | $2.29M | $2.26M | $1.97M | $1.79M | $1.92M | $1.42M | $882,000 | $894,000 |
| Share buybacks | — | — | — | $7.81M | $0 | $2.90M | $3.05M | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.